Text Size:AAA

人 DLL4 蛋白 (Fc 标签)

产品数据评论实验方法
反应性: Human  
应用 : ELISA  
    10171-MM15-50
    10171-MM15-200
    10171-MM15-100
    50 µg 
    200 µg 
    100 µg 
    Add to Cart
    反应性: Human  
    应用 : ELISA  
      10171-MM06-50
      10171-MM06-200
      10171-MM06-100
      10171-MM06-1
      50 µg 
      200 µg 
      100 µg 
      1 mg 
      Add to Cart
      反应性: Human  
      应用 : ELISA  
        10171-R003-50
        10171-R003-100
        10171-R003-1
        50 µg 
        100 µg 
        1 mg 
        Add to Cart
        反应性: Human  
        应用 : ELISA  
          10171-RP02-50
          10171-RP02-200
          10171-RP02-100
          50 µg 
          200 µg 
          100 µg 
          Add to Cart
          反应性: Human  
          应用 : ELISA  
            10171-RP01-400
            10171-RP01-200
            10171-RP01-100
            400 µg 
            200 µg 
            100 µg 
            Add to Cart
            反应性: Mouse  
            应用 : ELISA  
              50640-RP02-50
              50640-RP02-200
              50640-RP02-100
              50 µg 
              200 µg 
              100 µg 
              Add to Cart
              反应性: Mouse  
              应用 : ELISA  
                50640-R006-50
                50640-R006-100
                50 µg 
                100 µg 
                Add to Cart
                反应性: Mouse  
                应用 : 
                  50640-R004-50
                  50640-R004-100
                  50640-R004-1
                  50 µg 
                  100 µg 
                  1 mg 
                  Add to Cart
                  反应性: Mouse  
                  应用 : ELISA  
                    50640-RP01-400
                    50640-RP01-200
                    50640-RP01-100
                    400 µg 
                    200 µg 
                    100 µg 
                    Add to Cart

                    DLL4/Delta-like 4 ELISA配对抗体

                    检测限: 9.375 pg/ml
                    SEK50640-5
                    SEK50640-15
                    5 Plates 
                    15 Plates 
                    Add to Cart
                    检测限: 31.25 pg/ml
                    SEK10171-5
                    SEK10171-15
                    5 Plates 
                    15 Plates 
                    Add to Cart

                    DLL4/Delta-like 4 蛋白Related Products

                    Related Products

                    Featured Reagent Products

                    DLL4/Delta-like 4 protein 研究背景

                    Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.

                     DLL4/Delta-like 4 protein 参考资料
                  • Yan M, et al. (2007) Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res. 13(24): 7243-6.
                  • Sainson RC, et al. (2007) Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med. 13(9): 389-95.
                  • Martinez JC, et al. (2009) Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology. 54(5): 598-606.
                  • Li JL, et al. (2010) Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol. 6(7): 1099-103.
                  • 请注意:所有产品都是“仅用于科研,而不能用于诊断或治疗用途”